Hangzhou Tigermed Consulting Co., Ltd

XSEC:300347 Stock Report

Market Cap: CN¥47.4b

Hangzhou Tigermed Consulting Past Earnings Performance

Past criteria checks 1/6

Hangzhou Tigermed Consulting has been growing earnings at an average annual rate of 6.3%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 21.8% per year. Hangzhou Tigermed Consulting's return on equity is 4.2%, and it has net margins of 14.1%.

Key information

6.3%

Earnings growth rate

4.0%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate21.8%
Return on equity4.2%
Net Margin14.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Hangzhou Tigermed Consulting makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300347 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246,801959928238
30 Jun 247,0311,129922258
31 Mar 247,2401,691877261
31 Dec 237,3842,025874262
30 Sep 237,3302,281910259
30 Jun 237,2022,203847252
31 Mar 237,0722,057832242
01 Jan 237,0852,007804235
30 Sep 227,2252,698800228
30 Jun 226,7512,811800229
31 Mar 226,1292,937759222
01 Jan 225,2142,874703212
30 Sep 214,2872,213617201
30 Jun 213,7972,006573177
31 Mar 213,4441,950514165
31 Dec 203,1921,750475157
30 Sep 203,0731,632515145
30 Jun 202,9181,488487138
31 Mar 202,845951471132
31 Dec 192,803842457124
30 Sep 192,737682424103
30 Jun 192,60560641296
31 Mar 192,43652239993
31 Dec 182,30147238788
30 Sep 182,10741936181
30 Jun 181,977400313100
31 Mar 181,80535429175
31 Dec 171,68730128950
30 Sep 171,50024126444
30 Jun 171,3521822940
31 Mar 171,2551442880
31 Dec 161,1751412750
30 Sep 161,1501452450
30 Jun 161,0961592340
31 Mar 161,0151612200
31 Dec 159571562080
30 Sep 158621512040
30 Jun 158211471900
31 Mar 157251351670
31 Dec 146251251370
30 Sep 145101121110
30 Jun 14401102840
31 Mar 1437799720
31 Dec 1333794610

Quality Earnings: 300347 has a large one-off loss of CN¥368.8M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300347's current net profit margins (14.1%) are lower than last year (31.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300347's earnings have grown by 6.3% per year over the past 5 years.

Accelerating Growth: 300347's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300347 had negative earnings growth (-58%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).

Return on Equity

High ROE: 300347's Return on Equity (4.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 16:21
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hangzhou Tigermed Consulting Co., Ltd is covered by 39 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang LuoBOCI Research Ltd.
Linda LuBOCI Research Ltd.
Bo LiBofA Global Research